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The late Roger Bone [1, 2] coined the term “systemic in-
flammatory response syndrome, SIRS” more than 15 years
ago to describe a clinical entity highly prevalent in our in-
tensive care units (ICUs) [3, 4]. Patients with SIRS usually
present with fever and leukocytosis in addition to tachy-
chardia and tachypnea. Sepsis was defined as patients with
a documented bacterial infection and at least two SIRS
criteria [5]. It was also recognized by Bone and others
that many patients without infection have SIRS, later de-
fined as “aseptic SIRS” or “sterile shock” [6, 7]. Examples
of such conditions include acute respiratory distress syn-
drome, trauma, pancreatitis, major surgery, and ischemia-
reperfusion injury in patients recovering from shock.
The search for host molecules mediating SIRS has
been fruitless for a long period of time. It was initially
believed that SIRS is mediated by circulating proin-
flammatory mediators, such as tumor necrosis factor
α and interleukin 1β. This concept served as a basis
for conducting anticytokine clinical trials in a series
of conditions with SIRS—including sepsis—which
systematically failed. This led to a reappraisal of the
SIRS concept [8, 9]. It was shown that the systemic
compartment of critically ill patients with SIRS is already
profoundly anti-inflammatory [10–12]. This state is due
to the presence of high concentrations of natural soluble
inhibitors of proinflammatory cytokines, and monocyte
deactivating cytokines such as interleukin 10 [10, 12–14],
leading to systemic immune suppression [15]. In addition,
ICU therapies such as catecholamines, antimicrobials, and
sedatives have frequently unsuspected anti-inflammatory
effects [16]. Finally, a certain degree of inflammation
is necessary for neutralizing pathogens and clearing the
infectious process [17].
Patients with SIRS have in common tissue injury
with cells suffering or dying by necrosis. The systemic
consequences of tissue injury such as shock and severe
bacterial infections involve an integrated and complex
response of various systems including neural, immune,
hormonal, coagulation, and metabolic pathways [16].
It has long been thought that the immune system had
evolved with the discrimination between noninfectious
self from infectious nonself [18]. This concept can easily
be challenged in human pathophysiology. Clearly tissue
injury induces a systemic inflammatory response and
an immune dysfunction, in the absence of infection.
Conversely, an immune tolerance to infections is also
common, such as in bacteremia following tooth brushing.
Another concept of immunity was proposed in 1994 by
Matzinger [19, 20], the “danger model”. She hypoth-
esized that the immune system has evolved with the
discrimination of what is dangerous and what is not. In
addition, she has put forward the notion that in order
for the immune system to be significantly activated by
micro-organisms two simultaneous or sequential signals
are needed: one microbial signal, such as Gram-negative
lipopolysaccharide, and an endogenous “danger signal”,
a mediator signaling tissue injury [21]. This concept now
makes substantial sense to the ICU physician, and adds
meat to the bone of the “two-hit concept” frequently
observed in the pathogenesis of sepsis [7]. This notion
is also found in the stimulation of an adaptive immune
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response to a vaccine. A vaccine usually works better
when adjuvants create a certain amount of local tissue
injury, helping the recognition of the microbial antigen(s)
to enhance the immune response [22].
When significant, tissue injury alone is capable of
inducing the clinical syndrome known as SIRS [7]. In the
past 5 years candidate endogenous mediators potentially
sustaining these effects have been discovered. The most
prominent is certainly the high-mobility group box 1
(HMGB1) protein, but other endogenous molecules such
as antibacterial peptides, S100, and heat-shock proteins
may also play a role [23, 24]. These molecules, now known
as “alarmins” [25, 26] have in common an intracellular
compartmentalization in physiological conditions. In situ-
ations of cell suffering or cell death, alarmins are released
in the extracellular milieu and activate immune cells [27].
This is due to both an active secretion of alarmins by
injured (or activated) tissue cells, and a passive release
by cells undergoing necrosis. They also enhance immune
functions to microbial antigens [28]. Interestingly, some
of these “danger signals” share with pathogen-associated
molecular patterns the same innate immune receptors,
such as the Toll-like receptors (TLRs) [29].
HMGB1 functions as a DNA-binding molecule in nor-
mal cell physiology but can surprisingly act as a proin-
flammatory cytokine when released by cells [30]. It acti-
vates cells via TLR2, TLR4, and the receptor for advanced
glycosylation end-products [31, 32]. HMGB1 was initially
recognized as a critical endogenous mediator of lethality
in a model of murine endotoxemia [33]. HMGB1 release
was subsequently documented in a variety of inflamma-
tory and infectious animal models, as well as in critically
ill patients with sepsis and other conditions [34, 35]. In ani-
mal models of “aseptic SIRS,” such as pancreatitis, hemor-
rhagic shock, and trauma, HMGB1 blockade decreases the
inflammatory response and improves outcomes [36–38].
Coagulation has recently been demonstrated to be
a key innate element in the septic response [39]. A certain
degree of disseminated intravascular coagulation is almost
invariably associated with sepsis. This is due to the
abnormal intravascular expression of tissue factor and the
subsequent generation of thrombin. Decreased circulating
levels of endogenous proteins with antithrombin activity
(activated protein C, antithrombin, and tissue factor
pathway inhibitor) have also been reported by several
groups. In their contribution to Intensive Care Medicine
Hagiwara and collaborators [40] now report that treatment
of endotoxemic rats with antithrombin (AT) decreased
both lung injury and lethality. Importantly, they observed
lower lung and systemic HMGB1 concentrations and
lower circulating proinflammatory cytokines in AT-treated
rats. Antithrombin, similarly to the activated protein C,
exerts anti-inflammatory activity in addition to its anti-
thrombotic effects [41]. Interestingly, Hagiwara et al.
also show that murine macrophages cultured with AT
secrete less HMGB1 and proinflammatory mediators
in response to LPS, as a consequence of decreased
NF-κB activation. The anti-inflammatory effect of AT
on cells must therefore be at least partially direct and
not only mediated through a decreased thrombin activity.
Although it is known that AT binds to cells through an
interaction with glycosaminoglycans, the downstream
events remain poorly understood [41]. A large AT trial
failed to demonstrate a benefit in patients with severe
sepsis. However, a subgroup of patients who did not
concomitantly receive heparin seemed to benefit from
AT treatment [42, 43]. In vivo AT could exert both
direct and indirect protective effects. AT inhibits the
generation of thrombin with, as a consequence, decreased
deleterious disseminated intravascular coagulation and
possibly thrombin-associated inflammation. It may also
directly prevent tissue injury associated with sepsis by
interacting with endothelial and mononuclear cells and
the release of “danger signals” such as HMGB1. This is
in accordance with a recent report showing that HMGB1
promotes intravascular coagulation in a similar model,
suggesting a participation of this alarmin in the patho-
genesis of disseminated intravascular coagulation [44].
Although Hagiwara et al. found that AT treatment im-
proved outcome in their lipopolysaccharide model and
concomitantly decreased the inflammatory response and
HMGB1 release, they did not make a direct association
between these three aspects. These crucial points require
further studies.
We are progressing rapidly with our understanding of
the systemic consequences of tissue injury and the patho-
genesis of multiple organ dysfunction. Undoubtedly the
identification of alarmins—signaling tissue injury—and
their pathways of cell activation (“danger signals”) opens
a new and exciting field and will lead to the recognition
of new therapeutic targets. It appears conceptually sound
to block signals originating from tissue necrosis while
leaving intact those originating from pathogens. Targeting
HMGB1 in sepsis is tempting since it has been clearly
linked with lethality and is a late mediator, offering the
possibility of delayed treatment [45]. The history of sepsis
therapies, however, urges us to be cautious. Nature has
selected alarmins during evolution for good reasons, and
it is likely that some of the signals sent by these molecules
benefit our patients [46].
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